PARIS AND BOSTON–(BUSINESS WIRE)–Regulatory News:
Mauna Kea Technologies (Euronext: MKEA) (Paris: MKEA) (OTCQX: MKEAY) inventor of Cellvizio®The multidisciplinary platform for Confocal Miniprobe and Needle Laser Endomicroscopy (p/nCLE), announces that it has made publicly available and filed with the Autorité des Marchés financiers its Universal Registration Document for the fiscal year ended December 31, 2021. .
Mauna Kea Technologies universal registration document includes, in particular:
Financial Statement for 2021, consisting of the consolidated financial statements, annual financial statements and related audit reports;
Corporate Governance Report.
The Universal Registration Document is available on the Mauna Kea Technologies website, https://www.maunakeatech.com/fr/, under Investors/Financial Documents, and on the AMF website (www.amf-france.org) .
Next financial post:
Financial results for the first half of 2022, September 22, 2022, after market close.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and markets Cellvizio®, a real-time in vivo cellular imaging platform. This technology provides unique in vivo cellular imaging that allows clinicians to track disease progression over time, assess responses as they occur, classify areas of uncertainty, and guide surgical interventions. The Cellvizio platform is used in many countries around the world and in several medical specialties and changes the way doctors diagnose and treat patients. For more information visit www.maunakeatech.com.
This press release contains forward-looking statements regarding Mauna Kea Technologies and its business. All statements, other than statements of historical fact, included in this press release, including but not limited to statements about the financial condition, business, strategies, plans and management objectives of Mauna Kea Technologies with respect to future transactions, are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no guarantees can be given as to the realization of the projections expressed in these forward-looking statements, which are subject to numerous risks and uncertainties, including those described in Chapter 3 of the 2020 Mauna Kea Technologies Universal Registration Document filed with Autorité. des Marchés financiers (AMF) dated June 17, 2021 under number D-21-0566 and an amendment to the universal registration document filed with AMF on September 17, 2021, both available on the Company’s website (www.maunakeatech.fr). ), as well as risks associated with changes in the economic situation, financial markets and markets in which Mauna Kea Technologies is present. The forward-looking statements contained in this press release are also subject to risks unknown to Mauna Kea Technologies or which Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could cause the actual results, financial conditions, performance or achievements of Mauna Kea Technologies to differ materially from the results, financial conditions, performance or achievements set forth in these forward-looking statements. This press release and the information contained herein does not constitute an offer to sell or subscribe, nor an offer to buy or subscribe to Mauna Kea Technologies shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. In some jurisdictions, distribution of this press release may be restricted by local law. Persons into whose possession this document comes are responsible for compliance with all local regulations that apply to this document.
NewCap – Financial Communication
+33 (0)1 44 71 94 94